Trefoil Therapeutics Raises $28M and Eyes the Clinic for Cornea Drug

Trefoil Therapeutics Raises $28M and Eyes the Clinic for Cornea Drug

Play Episode Pause Episode

Mute/Unmute Episode Rewind 10 Seconds 1x Fast Forward 30 seconds

00:00 /

RSS Feed

Share

Link

Embed

Trefoil Therapeutics, which is developing treatments for diseases that affect the cornea, the outermost layer of the eye, has raised $28 million to move its lead drug candidate into human testing. The company is developing an engineered form of fibroblast growth factor-1 proteins (FGF-1) as a treatment for corneal diseases such as Fuchs? dystrophy, which [?]